TwentyFour Select Monthlyome Fund (LSE:SMIF) Research & Development: £0.00 Mil (TTM As of Mar. 2026)


LSE:SMIF TwentyFour Select Monthly Income Fund Ltd LSE:SMIF
44 GF Score
Price £0.86
GF Value £0.41
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is TwentyFour Select Monthlyome Fund Research & Development?

TwentyFour Select Monthlyome Fund LSE:SMIF +0.35% 44 Research & Development is £0.00 Mil as of Mar. 2026. GuruFocus rates LSE:SMIF with a GF Score™ of 44/100 and a GF Value™ of £0.41 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. TwentyFour Select Monthlyome Fund's Research & Development for the six months ended in Mar. 2026 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was £0.00 Mil.

TwentyFour Select Monthlyome Fund  (LSE:SMIF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TwentyFour Select Monthlyome Fund Research & Development Related Terms

TwentyFour Select Monthlyome Fund Research & Development Historical Data

* Premium members only.

The historical data trend for TwentyFour Select Monthlyome Fund's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TwentyFour Select Monthlyome Fund Research & Development Chart

TwentyFour Select Monthlyome Fund Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TwentyFour Select Monthlyome Fund Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:SMIF
44GF Score
TwentyFour Select Monthly Income Fund Ltd LSE:SMIF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TwentyFour Select Monthlyome Fund Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.00 Mil mean?
TwentyFour Select Monthlyome Fund (LSE:SMIF) has a Research & Development of £0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on TwentyFour Select Monthlyome Fund and its competitors.
Is TwentyFour Select Monthlyome Fund's Research & Development too high?
TwentyFour Select Monthlyome Fund's current Research & Development is £0.00 Mil. Overall, TwentyFour Select Monthlyome Fund has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TwentyFour Select Monthlyome Fund's Research & Development compare to BLK and BX?
TwentyFour Select Monthlyome Fund's Research & Development of £0.00 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Asset Management company?
A good Research & Development depends on the Asset Management industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TwentyFour Select Monthlyome Fund and its competitors. TwentyFour Select Monthlyome Fund's current Research & Development is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TwentyFour Select Monthlyome Fund stock overvalued right now?
Based on GuruFocus' analysis, TwentyFour Select Monthlyome Fund (LSE:SMIF) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.41, compared to a current price of £0.86 — trading 110.2% above its estimated fair value. The current Research & Development is £0.00 Mil. TwentyFour Select Monthlyome Fund's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TwentyFour Select Monthlyome Fund (LSE:SMIF), the current Research & Development is £0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TwentyFour Select Monthlyome Fund (LSE:SMIF) Overvalued in 2026?

Based on GuruFocus' analysis, TwentyFour Select Monthlyome Fund stock appears to be overvalued. The current stock price of £0.86 is trading 110.2% above its estimated GF Value™ of £0.41. GuruFocus considers TwentyFour Select Monthlyome Fund to be Significantly Overvalued.

Key valuation signals for LSE:SMIF:

  • Research & Development: £0.00 Mil
  • GF Value™: £0.41 vs. price of £0.86 (110.2% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the LSE:SMIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TwentyFour Select Monthlyome Fund Business Description

Address Les Banques, P.O. Box 255, Trafalgar Court, Saint Peter Port, GGY, GY1 3QL
TwentyFour Select Monthly Income Fund Ltd is a closed-ended investment company registered in Guernsey. Its investment objective is to generate attractive risk-adjusted returns, principally through income distributions. The company's investment policy is to invest in a diversified portfolio that comprises any category of credit security including bank capital, corporate bonds, high-yield bonds, leveraged loans, payment-in-kind notes, and asset-backed securities.
44GF Score

Get the complete analysis for LSE:SMIF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.86
Price
£0.41
GF Value